For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarterit ...

Obesity and diabetes have been two of the greatest public health challenges for decades. Many different diets and fads have promised the public ...

In response to the growing interest in glucagon-like peptide-1 (GLP-1) weight-loss medications and the cost challenges employers face to offer coverage, Liviniti, a national leader in PBM innovation, ...

PMGC Holdings Inc. (the "Company," "PMGC," "us," or "we") (Nasdaq:ELAB), a diversified holding company, today announced an update on its capital ...

A groundbreaking national poll conducted on behalf of the Diabetes Patient Advocacy Coalition (DPAC) reveals overwhelming bipartisan support for Medicare and Medicaid coverage of glucagon-like peptide ...

While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...

Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...

The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

Compared to other diabetes medications, GLP-1 drugs like Ozempic were associated with a lower risk for depression in a recent study.

Recent research found that weight loss drugs like Ozempic may be contributing to a national trend of thyroid cancer ...

For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with ...

GLP-1 receptor agonists are transforming obesity treatment, but manufacturing challenges must be addressed to meet rising ...